<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621424</url>
  </required_header>
  <id_info>
    <org_study_id>E1889-P</org_study_id>
    <secondary_id>RX14-009</secondary_id>
    <nct_id>NCT02621424</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for Dementia</brief_title>
  <acronym>rTMS for demen</acronym>
  <official_title>Repetitive Transcranial Magnetic Stimulation for Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to is to study if repetitive transcranial magnetic stimulation (rTMS) improves
      cognitive function in patients with neurodegenerative conditions which may manifest as mild
      to moderate cognitive impairment and, in late phase, dementia. This study also intends to
      investigate if the responses to rTMS intervention are either positively or negatively
      correlated with the initial severity of cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is that rTMS applied to the dorsolateral prefrontal cortex will lead
      to improved memory, language and executive function compared to patients who receive a sham,
      control treatment. The improvement is defined as having higher performance on the California
      Verbal Learning Test (CVLT-II). Secondary Hypotheses are that:

        -  1: rTMS- will lead to higher performance on secondary cognitive measures relating to
           executive function and naming compared to performance by participants in the sham
           treatment group at the termination of treatment; and that

        -  2: rTMS-induced memory improvement parallels changes in serum and cerebrospinal fluid
           (CSF) brain-derived neurotrophic factor (BDNF) levels after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">November 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline CVLT Scores After Treatment and 4 Months Later</measure>
    <time_frame>within a week following the final treatment session and 4 month later</time_frame>
    <description>Changes of California verbal learning test scores (CVLT) from baseline after treatment and 4 months later.
CVLT is 16 points scoring system. (minimum=0, maximum=16, higher the better memory).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Boston Naming After Treatment:</measure>
    <time_frame>within a week following the last treatment session and 4 months later</time_frame>
    <description>Changes in Boston Naming from baseline will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BDNF Levels in Serum and/or CSF After Treatment and 4 Months Later</measure>
    <time_frame>within a week following the last treatment session and 4 months later</time_frame>
    <description>Changes in BDNF levels in serum and/or CSF from baseline will be analyzed after treatment and 4 months later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Animal Fluency After Treatment and 4 Months Later</measure>
    <time_frame>immediately following treatment and 4 months later</time_frame>
    <description>Changes in Animal fluency from baseline after treatment and 4 months later will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Trail Making After Treatment and 4 Months Later</measure>
    <time_frame>immediately following treatment and 4 months later</time_frame>
    <description>changes in Trail making after treatment and 4 months later will be analyzed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Dementia</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>RTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham noise to block the sound of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RTMS</intervention_name>
    <description>stimulation of the brain with magnetic pulses</description>
    <arm_group_label>RTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>sham noise to block the sound of stimulation</description>
    <arm_group_label>sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veterans aged 55 years or older

          -  Diagnosed with Mild Cognitive Impairment (MCI) or dementia likely due to Alzheimer's
             disease.

          -  Ability to obtain a Motor Threshold, determined during the screening process.

          -  With an adequately stable condition and living environment to enable attendance at
             scheduled clinic visits.

          -  If on a prescription medication for cognition that medication dose will be stable for
             at least 4 weeks prior to randomization into the study and participant will be willing
             to remain on a stable regimen during the acute treatment phase.

          -  Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form
             to be signed by the participant, or a designated legal representative when the
             participant lacks decision making capacity prior to participating in any study-
             specific procedures or assessments.

        Exclusion Criteria:

          -  Patients with prior exposure to rTMS or electroconvulsive therapy (ECT).

          -  Unable to safely withdraw, at least two weeks prior to treatment commencement, from
             medications that substantially increase the risk of having seizures.

          -  Have a cardiac pacemaker or a cochlear implant.

          -  Have an implanted device deep brain stimulation or metal in the brain

          -  Current substance abuse not including caffeine or nicotine as determined by patient
             report or chart review.

          -  Active current suicidal intent or plan as determined by patient report or chart
             review.

          -  Current or Prior history of a seizure disorder as determined by patient report or
             chart review

          -  Traumatic brain injury within the last two months

          -  Participation in another concurrent interventional clinical trial

          -  Known current psychosis as determined by patient report or chart review.

          -  Current or prior history of a mass lesion, cerebral infarct or other non-cognitive,
             active central nervous system (CNS) disease that would increase the risk for seizure.

          -  Not fluent in English or a hearing impairment severe enough to impair comprehension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jauhtai J Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System, Palo Alto, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <results_first_submitted>February 11, 2020</results_first_submitted>
  <results_first_submitted_qc>May 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dementia</keyword>
  <keyword>Mild Cognitive Impairment (MCI)</keyword>
  <keyword>RTMS</keyword>
  <keyword>CVLT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02621424/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02621424/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two hundred and twenty nine patients were screened. 43 patients were eligible and signed consent. Three withdrew before randomization. Forty were randomized.</recruitment_details>
      <pre_assignment_details>Forty patients were randomized. Eight patient withdrew before treatment started. Thirty two patients started the treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RTMS</title>
          <description>repetitive transcranial magnetic stimulation
RTMS: stimulation of the brain with magnetic pulses</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>sham noise to block the sound of treatment
sham: sham noise to block the sound of stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RTMS</title>
          <description>repetitive transcranial magnetic stimulation
RTMS: stimulation of the brain with magnetic pulses</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>sham noise to block the sound of treatment
sham: sham noise to block the sound of stimulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.4" spread="7.4"/>
                    <measurement group_id="B2" value="70.4" spread="7.7"/>
                    <measurement group_id="B3" value="70.8" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>neuropsychological testing</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline CVLT Scores After Treatment and 4 Months Later</title>
        <description>Changes of California verbal learning test scores (CVLT) from baseline after treatment and 4 months later.
CVLT is 16 points scoring system. (minimum=0, maximum=16, higher the better memory).</description>
        <time_frame>within a week following the final treatment session and 4 month later</time_frame>
        <population>Sham arm: 18 started, two withdrew and two had incorrect collection of neuropsych data and thus excluded from the analysis (18-4=14) Active arm: 14 started, one withdrew, thus 13 sets of data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RTMS</title>
            <description>repetitive transcranial magnetic stimulation
RTMS: stimulation of the brain with magnetic pulses</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>sham noise to block the sound of treatment
sham: sham noise to block the sound of stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline CVLT Scores After Treatment and 4 Months Later</title>
          <description>Changes of California verbal learning test scores (CVLT) from baseline after treatment and 4 months later.
CVLT is 16 points scoring system. (minimum=0, maximum=16, higher the better memory).</description>
          <population>Sham arm: 18 started, two withdrew and two had incorrect collection of neuropsych data and thus excluded from the analysis (18-4=14) Active arm: 14 started, one withdrew, thus 13 sets of data were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="3.9"/>
                    <measurement group_id="O2" value="10.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Boston Naming After Treatment:</title>
        <description>Changes in Boston Naming from baseline will be analyzed</description>
        <time_frame>within a week following the last treatment session and 4 months later</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in BDNF Levels in Serum and/or CSF After Treatment and 4 Months Later</title>
        <description>Changes in BDNF levels in serum and/or CSF from baseline will be analyzed after treatment and 4 months later</description>
        <time_frame>within a week following the last treatment session and 4 months later</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Animal Fluency After Treatment and 4 Months Later</title>
        <description>Changes in Animal fluency from baseline after treatment and 4 months later will be analyzed.</description>
        <time_frame>immediately following treatment and 4 months later</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Trail Making After Treatment and 4 Months Later</title>
        <description>changes in Trail making after treatment and 4 months later will be analyzed</description>
        <time_frame>immediately following treatment and 4 months later</time_frame>
        <posting_date>02/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RTMS</title>
          <description>repetitive transcranial magnetic stimulation
mild headache and irritation at the site of stimulation were reported and thought to be treatment-related. These event were mild and only lasted a day or two.
There were other reported events and were reviewed with the IRB. They were determined to be not related to RTMS treatment.</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>sham noise to block the sound of treatment Low amplitude electrical stimulation was used to simulate the sensation of RTMS. The electrical stimulation to the scalp can cause mild sense of irritation, which only occurs when the stimulation is turned on.
There were other reported events and were reviewed with the IRB. They were determined to be not related to RTMS treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jauhtai Cheng, MD, Staff Neurologist</name_or_title>
      <organization>VA Palo Alto</organization>
      <phone>650-493-5000 ext 63617</phone>
      <email>jauhtai.cheng2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

